Vaccine and Emerging Infections Research, Human Health Therapeutics Research Centre, National Research Council, Ottawa, ON K1A 0R6, Canada.
ACS Infect Dis. 2022 Jul 8;8(7):1347-1355. doi: 10.1021/acsinfecdis.2c00184. Epub 2022 Jun 8.
was added to the World Health Organization's priority pathogen list for research and development of new antibiotics in 2017. Alongside the development of new antibiotics to fight antimicrobial-resistant , vaccines would be an appealing addition to the toolbox health professionals have against this bacteria, which causes life-threatening respiratory infections. Recently, the structure of a novel immunogenic terminal carbohydrate moiety on the cell surface of was elucidated, consisting of a 3--methyl (1→4)-α-d-rhamnan pentasaccharide. As isolating this oligosaccharide from in sufficient amounts for producing a conjugate vaccine is challenging, herein we describe the synthesis of 3-methyl d-rhamnose oligosaccharide. We also report the conjugation of the synthetic pentasaccharide to human serum albumin and its resulting immunogenicity.
2017 年，被世界卫生组织列入优先病原体名单，以研究和开发新的抗生素。除了开发新的抗生素来对抗抗药性之外，疫苗将是对抗这种细菌的工具包中一个吸引人的补充，这种细菌会导致危及生命的呼吸道感染。最近，阐明了 细胞表面新型免疫原性末端碳水化合物部分的结构，由 3--甲基（1→4）-α-d-鼠李糖五聚糖组成。由于从 中分离出足够用于生产缀合疫苗的这种寡糖具有挑战性，在此我们描述了 3-甲基-d-鼠李糖寡糖的合成。我们还报告了合成五聚糖与人血清白蛋白的缀合及其免疫原性。
